Why are you looking at Cidara Therapeutics?
Capability
Service linesRESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Work mix: 100% prime · 0% sub · primary NAICS 541714 / PSC AN14 HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES
Where they win
Sole agencyRecompete exposure: None
No incumbent recompetes detected in the next 24 months.
Agency buyer map
1 buyersRecompete exposure
NoneNo incumbent recompetes detected in the next 24 months.
No incumbent recompetes detected in the next 24 months.
GET THE FULL BRIEF
Get Cidara Therapeutics’s recompete exposure, top agencies and teaming history
The outlook above is free to read and verify — an estimated $58.1M in play. Enter a work email for two figures the page cannot show.
“SCOUT saves the hours of analysis that capture and proposal teams cannot afford to lose by delivering analyzed intelligence. Incumbent history, competitive positioning, and agency buying patterns get synthesized into…”
Enter your company name and we'll build the page.
Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →
Frequently asked questions
What federal contracts does Cidara Therapeutics hold?
Cidara Therapeutics (UEI FKP3JZ9RUNY9) shows $58.1M across 1 award actions in SCOUT’s public USASpending-backed profile, with Department of Health and Human Services (HHS) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.
Which agencies does Cidara Therapeutics work with?
Cidara Therapeutics’s firm-wide obligated mix is led by Department of Health and Human Services (HHS) (100%).
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →